Virtual Webinar
7.30 pm –8.30 pm
Thursday September 15, 2022

BIO’s

Professor Paul Griffin
Director of Infectious Diseases, Mater and Associate Professor of Medicine, University of Queensland. Fellowships in Infectious Diseases, Clinical Microbiology and Tropical Medicine. Principal Investigator/Medical Director, Nucleus Network: Principal Investigator on over 125 clinical trials including 6 vaccines for COVID-19. Microbiologist: Particularly clinical applications of f
aecalmetagenomic sequencing. Director/Scientific Advisory Board member, Immunisation Coalition: vaccine education/advocacy, has become a media spokesperson during the COVID-19 pandemic featuring on prominent programs across television, radio, print and online including The Project, Sunrise, Today Show, A Current Affair and internationally including BBC and CTV.

Assoc. Professor Peter Foley
Associate Professor Peter Foley graduated MBBS, BMedSc from Monash University in 1987, and MD from The University of Melbourne in 1996. He completed his dermatology training in Melbourne, obtaining Fellowship of the Australasian College of Dermatologists in 1997. He is Director of Research at the Skin Health Institute and the Head of Dermatology Research at St Vincent’s Hospital Melbourne. He currently holds the position of Associate Professor, Department of Medicine at The University of Melbourne. In addition to running a busy private practice, he is a visiting medical officer to the Photobiology, Dermatology Biologics, and Dermatology Investigation clinics at St Vincent’s Hospital Melbourne, and the Phototherapy and Biologics clinics at the Skin
Health Institute.

AGENDA

7:30 PM–7:45 PM
Associate Professor Peter Foley -Tailored Dosing

7:45 PM–8:20 PM
Professor Paul Griffin –Monkey Pox Virus Update

8:20 PM–8:30 PM
Q & A

8:30 PM
Close

Novartis Privacy and Collection Statement:
Your personal information will be processed in accordance with the Novartis Privacy Policy at https://www.novartis.com.au/privacy-policy. Your information, including any information forwarded to the Novartis Patient Safety department, may be processed and stored on servers located in jurisdictions outside of the country in which it was collected.
In accordance with the Code of Conduct for the prescription medicines industry in Australia, any cost (for example travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional must not be paid for or subsidised by Novartis. Date of preparation AUG 2022 AU-21891